Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States (CEPHEUS)

This study has been completed.
Sponsor:
Collaborator:
ClinArt International Company
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01031277
First received: December 11, 2009
Last updated: May 24, 2011
Last verified: May 2011

December 11, 2009
May 24, 2011
November 2009
July 2010   (final data collection date for primary outcome measure)
To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01031277 on ClinicalTrials.gov Archive Site
  • Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III). [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • The proportion of patients reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations: primary/secondary prevention patients, and patients with metabolic syndrome (according to NCEP III definition) [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • The proportion of patients reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the following sub-populations: primary/secondary prevention patients, and patients with metabolic syndrome. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
  • To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia. [ Time Frame: 6 months- One visit only, no follow up visits. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
Centralized Gulf States Survey on the Undertreatment of Hypercholesterolemia

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:

    • Primary/secondary prevention patients.
    • Patients with metabolic syndrome.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Not Provided
Retention:   None Retained
Description:

Whole blood

Non-Probability Sample

Inhabitants of Gulf States visiting their cardiologist for regular follow-up of their hypercholesterolaemia treatment

Hypercholesterolemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1000
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Race
  • On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
  • Subject must sign informed consent

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Arab Emirates
 
NCT01031277
NIS-GU-CRE-2009/1, SRP-CB-CRE-2006/01
No
MC MD, AstraZeneca Gulf States
AstraZeneca
ClinArt International Company
Study Chair: Prof. Wael Al Mahmeed Shaikh Khalifa Medical City
AstraZeneca
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP